Touya, Maëlys
Lawrence, Debra F.
Kangethe, Anne
Chrones, Lambros
Evangelatos, Themmi
Polson, Michael
Article History
Received: 20 January 2021
Accepted: 14 February 2022
First Online: 1 March 2022
Declarations
:
: All methods were carried out in accordance with relevant guidelines and regulations. This study is exempt from Institutional Review Board requirements because it includes analyses of administrative claims datasets and fulfills the following exemption requirements: (1) the study does not include any individually identifiable health information, (2) the authors are authorized by the medical/pharmacy database manager of Magellan Rx Management to use the Protected Health Information (PHI) in conducting analyses performed under the “Treatment, Payment, Health Care Operations” provision of Health Insurance Portability and Accountability Act of 1996 (HIPAA), and (3) the authors are bound to Magellan by confidentiality standards that protect individually identifiable health information, including HIPAA-compliant procedures for storage, transmission, release, and disposal of PHI.
: N/A.
: M.P. is an employee of Magellan Method, a Division of Magellan Rx Management, contracted by Takeda Pharmaceuticals U.S.A., Inc., and Lundbeck LLC to conduct the research for this study. A.K. was an employee of Magellan Method at the time of the study. L.C., T.E., and D.F.L. are employees of Takeda Pharmaceuticals U.S.A, Inc. M.T. is an employee of Lundbeck LLC.